Introduction
============

Lung cancer is one of the most common cancers and is the leading cause of cancer-related deaths worldwide. There were 1.8 million new diagnoses of lung cancer in 2012, accounting for 13% of the global cancer burden.[@b1-cmar-10-697] The incidence and mortality rates of lung cancer in China were estimated to be 0.7 and 0.6 million cases in 2015.[@b2-cmar-10-697] Although smoking is the key risk factor for lung cancer, there are lung cancer patients without a smoking history.[@b3-cmar-10-697] An increasing number of studies have proven that genetic factors play a key role in the development of nonsmall cell lung cancer (NSCLC), which accounts for approximately 80% of lung cancer cases.

MicroRNAs (miRNAs) are a group of short RNAs with 20--23 noncoding nucleotides that play important modulatory roles in various biological processes through posttranscriptional regulation. It is estimated that miRNAs regulate more than 30% of all human genes[@b4-cmar-10-697],[@b5-cmar-10-697] and are involved in crucial physiological processes, such as proliferation, apoptosis, differentiation, tumorigenesis, and cancer metastasis.[@b5-cmar-10-697]--[@b8-cmar-10-697] Recently, studies have indicated the aberrant expression of miRNAs in human cancers,[@b9-cmar-10-697]--[@b11-cmar-10-697] including lung cancer.[@b12-cmar-10-697] Moreover, Sheervalilou et al[@b13-cmar-10-697] showed that aberrant expression of miRNAs in lung cancer might induce lung tumorigenesis. On the other hand, functional studies have shown that single nucleotide polymorphisms (SNPs) in miRNA genes may be associated with miRNA expression[@b14-cmar-10-697],[@b15-cmar-10-697] and target gene expression.[@b16-cmar-10-697] Moreover, several studies have shown that SNPs in miRNA are associated with human cancers,[@b17-cmar-10-697]--[@b21-cmar-10-697] for example, in 2014, Wang et al reported that rs3746444 in *miR-499a* and rs11614913 in *miR-196a2* were associated with lung cancer.[@b22-cmar-10-697]

In the current study, we evaluated the association of SNPs (rs11134527 in *pri-miR-218-2*; rs74693964 in *pri-miR-145*; rs6062251 in *pri-miR-133a-2*; rs4705343 in *pri-miR-143*) in miRNA genes with NSCLC in a Han Chinese population. Our results revealed the role of genetic variations in the miRNA genes in the development of NSCLC in a Han Chinese population.

Materials and methods
=====================

Ethics statement
----------------

This study was approved by the Institutional Review Board of the No. 1 and No. 3 Affiliated Hospitals of Kunming Medical University. The methods used in this investigation were in accordance with the approved guidelines and the principles expressed in the Helsinki Declaration of 1975, which was revised in 2008. All participants provided written informed consent.

Subjects
--------

The NSCLC group included 452 patients (308 males and 144 females) who were diagnosed with NSCLC at the No. 1 and No. 3 Affiliated Hospitals of Kunming Medical University from July 2014 to May 2016. The histological type of NSCLC was identified according to the World Health Organization (WHO 2004) classifications.[@b23-cmar-10-697] The pathologic stage was determined according to the International System for Staging Lung Cancer.[@b24-cmar-10-697] Based on the pathomorphological reports, the NSCLC cases included adenocarcinoma (AC), squamous cell carcinoma (SCC), and both AC and SCC. NSCLC patients with a prior history of primary cancer other than lung cancer were excluded from the current study. Clinical characteristics and data, such as gender, age, family history of cancer, and histological type of cancer, were obtained. The healthy control group included 452 subjects (318 males and 134 females) who had no family history of NSCLC and were recruited from a population undergoing routine health checkups at the No. 1 and No. 3 Affiliated Hospitals of Kunming Medical University. All participants self-reported as ethnic Hans and lived within approximately the same geographic region (Yunnan Province, Southwest China).

SNP genotyping
--------------

Genomic DNA was extracted from peripheral lymphocytes using the QIAamp Blood Mini Kit (Qiagen, Hilden, Germany). Four SNPs in miRNA genes, namely, rs11134527, rs74693964, rs6062251, and rs4705343, were genotyped using PCR amplification with a TaqMan assay. Primers and probes were purchased from Applied Biosystems (Foster City, CA, USA). To identify the accuracy of SNP genotyping by the TaqMan assay, three positive controls and one negative control were genotyped via TaqMan assay at the same time.

Statistical analysis
--------------------

SPSS 19.0 (IBM Corporation, Armonk, NY, USA) and Microsoft Excel were used to conduct the statistical analyses. The Student's *t*-test or one-way analysis of variance was used to test the quantitative variables, and the categorical data were compared by chi-square test. The allelic and genotypic frequencies of the four SNPs were calculated by the direct counting method. Hardy--Weinberg equilibrium (HWE) was tested for the SNPs in both the NSCLC and control groups. The genetic association between the SNPs in miRNA genes and NSCLC susceptibility was calculated using a binary logistic regression with gender and age as the covariates, and the ORs with the associated 95% CIs of allele-specific risks were also calculated. In addition, the Hosmer--Lemeshow test and the Nagelkerke *R*^2^ were employed to establish the optimal model. The association between genotypes of the SNPs and NSCLC was analyzed using the inheritance model analysis of SNPStats software.[@b25-cmar-10-697] Five models including the codominant, dominant, recessive, overdominant, and log-additive were analyzed. The best-fit inheritance model was determined using the Akaike information criterion and Bayesian information criterion, which possesses the minimal Akaike information criterion and Bayesian information criterion values. A *P* value less than 0.05 was considered statistically significant.

Results
=======

Subject characteristics
-----------------------

[Table 1](#t1-cmar-10-697){ref-type="table"} lists the characteristics of the enrolled subjects. There were no age or gender differences between the NSCLC and control groups (*P*\>0.05). In the NSCLC individuals, 271 had AC, 169 had SCC, and 12 had both AC and SCC. There were 70 patients in pathological stage I, 77 in stage II, 161 in stage III, and 144 in stage IV.

Association of the four SNPs with NSCLC
---------------------------------------

The allelic and genotypic frequencies of the four SNPs in the miRNAs are displayed in [Table 2](#t2-cmar-10-697){ref-type="table"}. Genotypic frequencies of the four SNPs were in HWE for the case and control groups (*P*\>0.05). The allelic and genotypic frequencies of rs11134527 were significantly different in the NSCLC and control groups (*P*=0.025 and 0.045, respectively). The A allele of rs11134527 occurred more frequently in the NSCLC group compared with the control group (OR=1.24; 95% CI: 1.03--1.50). The allelic frequencies for rs4705343 were significantly different between the NSCLC and control groups (*P*=0.029). The frequency of the A allele for rs4705343 was significantly higher in the control group than that in the NSCLC group (OR=0.80; 95% CI: 0.66--0.98). The allelic and genotypic frequencies of rs74693964 and rs6062251 showed no significant difference between the NSCLC and control groups (*P*\>0.05).

Model of inheritance analysis of the four SNPs with NSCLC
---------------------------------------------------------

[Tables 3](#t3-cmar-10-697){ref-type="table"}[](#t4-cmar-10-697){ref-type="table"}[](#t5-cmar-10-697){ref-type="table"}--[6](#t6-cmar-10-697){ref-type="table"} present the results of the analyses of the different inheritance model for the four SNPs. The genotypic frequency of rs11134527 A/G+G/G was significantly different from A/A (*P*=0.011) under the dominant model between the NSCLC and control groups. The A/G+GG genotype was associated with a decreased risk of NSCLC (OR=0.69; 95% CI: 0.52--0.92). The genotypic frequencies of rs4705343 were significantly different under the log-additive model between the NSCLC and control groups (*P*=0.036). The 2CC+T/C genotype was associated with a higher risk of NSCLC (OR=1.25; 95% CI: 1.01--1.53).

Association analysis of the four SNPs with different pathologic stages
----------------------------------------------------------------------

[Table 7](#t7-cmar-10-697){ref-type="table"} shows the results of the association analysis of the four SNPs between pathologic stages I+II and III+IV. There were no significant differences in the allelic and genotypic frequencies for the four SNPs between pathologic stages I+II and III+IV (*P*\>0.05).

Association analysis of the four SNPs with AC and SCC
-----------------------------------------------------

Our results showed that the allelic and genotypic frequencies of rs11134527 were significantly different between AC and SCC (*P*=0.005 and 0.015, respectively). The A allele was associated with SCC (OR=0.65; 95% CI: 0.48--0.88) ([Table 8](#t8-cmar-10-697){ref-type="table"}).

Discussion
==========

Recently, many studies have reported the association of miRNA genes and NSCLC. In addition, several studies have been carried out to evaluate the association of SNPs located in miRNA genes with the susceptibility of cancers, including NSCLC. In the current study, we analyzed the association of four SNPs (rs11134527 in *pri-miR-218-2*; rs74693964 in *pri-miR-145*; rs6062251 in *pri-miR-133a-2*; rs4705343 in *pri-miR-143*) in miRNAs with NSCLC susceptibility in a Han Chinese population. Our results showed that the A allele of rs11134527 might be a risk factor and that the T allele of rs4705343 might be a protective factor for NSCLC in this Han Chinese population.

miR-218 has been reported to be downregulated in various cancers.[@b26-cmar-10-697]--[@b28-cmar-10-697] In 2010, Wu et al[@b29-cmar-10-697] reported that reduced expression of miR-218 was associated with worse survival in lung cancer. Then, Kumamoto et al[@b30-cmar-10-697] found that ectopic expression of miR-218 significantly inhibited cancer cell migration and invasion in lung cancer. In addition, some studies have found associations between rs11134527, located at *pri-miR-218-2*, and the risk of different human cancers, such as esophageal squamous cell carcinoma (ESCC),[@b31-cmar-10-697] cervical cancer,[@b32-cmar-10-697],[@b33-cmar-10-697] and hepatocellular carcinoma. Our results also showed that the genotypic and allelic frequencies of rs11134527 were significantly different between the NSCLC and control groups. Allele A of rs11134527 was associated with a higher risk of NSCLC. Our results are consistent with previous studies performed on cervical cancer that found that the rs11134527 GG genotype was associated with a decreased risk of cervical carcinoma[@b32-cmar-10-697],[@b33-cmar-10-697] and ESCC,[@b31-cmar-10-697] which indicated that rs11134527 might alter the expression of miR-218 and be associated with cancer. However, Zhang et al[@b34-cmar-10-697] and Zhang et al[@b35-cmar-10-697] found that there was no association of this SNP with ESCC and hepatocellular carcinoma, respectively. The reason for these different results might be the different cancer types.

miR-143, a tumor suppressor of various types of human cancer, has been demonstrated to play crucial roles in tumor growth, migration, and invasion.[@b36-cmar-10-697]--[@b38-cmar-10-697] In lung cancer, miR-143 can inhibit the genesis and development of tumors through directly suppressing the expression of its target genes.[@b39-cmar-10-697],[@b40-cmar-10-697] Recently, an integrated bioinformatics analysis showed that miR-143 was downregulated in NSCLC.[@b41-cmar-10-697] These data indicate that miR-143 is important for the initiation and development of human cancers. Based on this, other studies have investigated the association of SNPs in miR-143 with human cancers and found that SNPs (such as rs4705343 and rs353292) in *miR-143* are associated with several cancers.[@b42-cmar-10-697]--[@b44-cmar-10-697] In the current study, we found that allele T of rs4705343 was associated with a decreased risk of NSCLC, which is in agreement with the results of a case--control study on cervical SCC.[@b45-cmar-10-697] These results also indicate that rs4705343 in miR-143 plays an important role in NSCLC and cervical SCC.

Downregulation of miR-145 and miR-133a has been reported in cancers. Several SNPs located in the flanking region of the *miR-145* gene were demonstrated to be associated with the expression of miR-145 and disease susceptibility.[@b43-cmar-10-697],[@b45-cmar-10-697]--[@b47-cmar-10-697] In 2016, Xiao et al[@b48-cmar-10-697] identified miR-133 as a biomarker for lung cancer. In addition, several studies have found an association between SNPs in the *miR-133* gene (rs8089787, rs9948906, rs13040413, and rs200375711) with different diseases.[@b49-cmar-10-697],[@b50-cmar-10-697] In the current study, we analyzed the association of rs74693964 in *miR-145* and rs6062251 in *miR-133a2* with NSCLC. However, we did not find an association of rs74693964 in *pri-miR-145* or rs6062251 in *pri-miR-133a-2* with NSCLC in the current population.

A limitation of the present study is that we did not ascertain the smoking status of the control individuals, making it difficult to perform future analyses of such exposure variables or a gene--smoking interaction analysis. This limitation may neutralize the effect of smoking and expose the effects of genetic variants in our study.

Conclusion
==========

In the current study, we investigated the association of four SNPs located in four tumor suppressor miRNA genes (*pri-miR-218-2*, *pri-miR-143*, *pri-miR-145*, and *pri-miR-133a-2*) with NSCLC in a Chinese Han population. Our results showed that the A allele of rs11134527 in *pri-miR-218-2* might be a risk factor for lung cancer. In addition, the T allele of rs4705343 in *pri-miR-143* might be associated with a decreased risk of NSCLC. Our findings provide evidence that rs11134527 in *pri-miR-218-2* and rs4705343 in *pri-miR-143* may be new biomarkers for NSCLC. However, we analyzed the distribution of the SNPs between Asian and European populations (<http://asia.ensembl.org/Homo_sapiens/Info/Index>) and found that the allelic frequencies selected in the current study were significantly different between these two populations ([Table 9](#t9-cmar-10-697){ref-type="table"}). This result might suggest that it is necessary to evaluate the association of these SNPs with NSCLC in different populations before these SNPs are used as new biomarkers for NSCLC.
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###### 

Clinical characteristics of the subjects enrolled in the current study

  Characteristics                              NSCLC         Control       *P*-value
  -------------------------------------------- ------------- ------------- -----------
  N                                            452           452           
  Ages, mean ± SD (years)                      55.71±10.01   55.96±10.72   0.112
  Gender (male/female)                         308/144       318/134       0.471
  Adenocarcinoma                               271 (59.9%)                 
  Squamous cell carcinoma                      169 (37.4%)                 
  Adenocarcinoma and squamous cell carcinoma   12 (2.7%)                   
  Clinical stage                                                           
   I                                           70 (15.5%)                  
   II                                          77 (17.0%)                  
   III                                         161 (35.6%)                 
   IV                                          144 (31.9%)                 

**Abbreviation:** NSCLC, nonsmall cell lung cancer.

###### 

Comparison of genotypic and allelic distribution of the four SNPs between NSCLC and control groups (after adjusting for gender and age)

  SNP          Genotype, n (%)   *P*-value    Allele, n (%)   *P*-value   OR (95% CI)                        
  ------------ ----------------- ------------ --------------- ----------- ------------- ------------ ------- -------------------
  rs11134527   A/A               A/G          G/G                         A             G                    
   NSCLC       181 (40.0)        195 (43.1)   76 (16.8)       0.045       557 (61.6)    347 (38.4)   0.025   1.24 (1.03--1.50)
   Control     145 (32.1)        220 (48.7)   87 (19.2)                   510 (56.4)    394 (43.6)           
  rs74693964   C/C               C/T          T/T                         C             T                    
   NSCLC       422 (93.4)        30 (6.6)     0 (0.0)         0.264       874 (96.7)    30 (3.3)     0.319   0.76 (0.44--1.31)
   Control     430 (95.1)        21 (4.6)     1 (0.2)                     881 (97.5)    23 (2.5)             
  rs6062251    C/C               C/T          T/T                         C             T                    
   NSCLC       43 (9.5)          217 (48.0)   192 (42.5)      0.338       303 (33.5)    601 (66.5)   0.395   1.90 (0.89--1.33)
   Control     46 (10.2)         195 (43.1)   211 (46.7)                  287 (31.7)    617 (68.3)           
  rs4705343    T/T               T/C          C/C                         T             C                    
   NSCLC       204 (45.1)        196 (43.4)   52 (11.5)       0.092       604 (66.8)    300 (33.2)   0.029   0.80 (0.66--0.98)
   Control     232 (51.3)        183 (40.5)   37 (8.2)                    647 (71.6)    257 (28.4)           

**Abbreviations:** NSCLC, nonsmall cell lung cancer; SNP, single nucleotide polymorphism.

###### 

Inheritance analysis of rs11134527 in *pri-miR-218-2* between NSCLC and control groups (after adjusting for gender and age)

  Model          Genotype     Control, n (%)   NSCLC, n (%)        OR (95% CI)         *P*-value   AIC      BIC
  -------------- ------------ ---------------- ------------------- ------------------- ----------- -------- --------
  Codominant     A/A          145 (32.1)       181 (40)            1.00                0.039       1334.6   1603.7
  A/G            220 (48.7)   195 (43.1)       0.69 (0.51--0.94)                                            
  G/G            87 (19.2)    76 (16.8)        0.69 (0.46--1.02)                                            
  Dominant       A/A          145 (32.1)       181 (40)            1.00                0.011       1332.6   1596.9
  A/G-G/G        307 (67.9)   271 (60)         0.69 (0.52--0.92)                                            
  Recessive      A/A-A/G      365 (80.8)       376 (83.2)          1.00                0.340       1338.1   1602.5
  G/G            87 (19.2)    76 (16.8)        0.84 (0.59--1.20)                                            
  Overdominant   A/A-G/G      232 (51.3)       257 (56.9)          1.00                0.086       1336.1   1600.5
  A/G            220 (48.7)   195 (43.1)       0.79 (0.60--1.04)                                            
  Log-additive   --           --               --                  0.81 (0.66--0.98)   0.026       1334.1   1598.5

**Abbreviations:** AIC, Akaike information criterion; BIC, Bayesian information criterion; NSCLC, nonsmall cell lung cancer.

###### 

Inheritance analysis of 74693964 in *pri-miR-145* between NSCLC and control groups (after adjusting for gender and age)

  Model          Genotype   Control, n (%)   NSCLC, n (%)        OR (95% CI)         *P*-value   AIC      BIC
  -------------- ---------- ---------------- ------------------- ------------------- ----------- -------- --------
  Codominant     C/C        430 (95.1)       422 (93.4)          1.00                0.110       1336.6   1605.8
  C/T            21 (4.7)   30 (6.6)         1.66 (0.91--3.05)                                            
  T/T            1 (0.2)    0 (0.0)          0.00 (0.00--NA)                                              
  Dominant       C/C        430 (95.1)       422 (93.4)          1.00                0.130       1336.8   1601.2
  C/T-T/T        22 (4.9)   30 (6.6)         1.57 (0.87--2.86)                                            
  Recessive      C/C-C/T    451 (99.8)       452 (100)           1.00                0.200       1337.4   1601.8
  T/T            1 (0.2)    0 (0.0)          0.00 (0.00--NA)                                              
  Overdominant   C/C-T/T    431 (95.3)       422 (93.4)          1.00                0.094       1336.2   1600.6
  C/T            21 (4.7)   30 (6.6)         1.67 (0.91--3.06)                                            
  Log-additive   --         --               --                  1.47 (0.82--2.62)   0.190       1337.4   1601.7

**Abbreviations:** AIC, Akaike information criterion; BIC, Bayesian information criterion; NSCLC, nonsmall cell lung cancer.

###### 

Inheritance analysis of rs6062251 in *pri-miR-133a-2* between NSCLC and control groups (after adjusting for gender and age)

  Model          Genotype     Control, n (%)   NSCLC, n (%)        OR (95% CI)         *P*-value   AIC      BIC
  -------------- ------------ ---------------- ------------------- ------------------- ----------- -------- --------
  Codominant     T/T          211 (46.7)       192 (42.5)          1.00                0.340       1338.9   1608.1
  C/T            195 (43.1)   217 (48)         1.23 (0.92--1.64)                                            
  C/C            46 (10.2)    43 (9.5)         1.01 (0.63--1.63)                                            
  Dominant       T/T          211 (46.7)       192 (42.5)          1.00                0.220       1337.5   1601.9
  C/T-C/C        241 (53.3)   260 (57.5)       1.19 (0.90--1.56)                                            
  Recessive      T/T-C/T      406 (89.8)       409 (90.5)          1.00                0.690       1338.9   1603.3
  C/C            46 (10.2)    43 (9.5)         0.91 (0.58--1.44)                                            
  Overdominant   T/T-C/C      257 (56.9)       235 (52)            1.00                0.140       1336.9   1601.3
  C/T            195 (43.1)   217 (48)         1.23 (0.93--1.61)                                            
  Log-additive   --           --               --                  1.08 (0.88--1.34)   0.450       1260.4   1279.6

**Abbreviations:** AIC, Akaike information criterion; BIC, Bayesian information criterion; NSCLC, nonsmall cell lung cancer.

###### 

Inheritance analysis of rs4705343 in *pri-miR-143* between NSCLC and control groups (after adjusting for gender and age)

  Model          Genotype     Control, n (%)   NSCLC, n (%)        OR (95% CI)         *P*-value   AIC      BIC
  -------------- ------------ ---------------- ------------------- ------------------- ----------- -------- --------
  Codominant     T/T          232 (51.3)       204 (45.1)          1.00                0.110       1336.7   1605.8
  T/C            183 (40.5)   196 (43.4)       1.25 (0.94--1.67)                                            
  C/C            37 (8.2)     52 (11.5)        1.54 (0.96--2.48)                                            
  Dominant       T/T          232 (51.3)       204 (45.1)          1.00                0.056       1335.4   1599.8
  T/C-C/C        220 (48.7)   248 (54.9)       1.30 (0.99--1.71)                                            
  Recessive      T/T-T/C      415 (91.8)       400 (88.5)          1.00                0.160       1337.1   1601.4
  C/C            37 (8.2)     52 (11.5)        1.39 (0.88--2.19)                                            
  Overdominant   T/T-C/C      269 (59.5)       256 (56.6)          1.00                0.280       1337.9   1602.2
  T/C            183 (40.5)   196 (43.4)       1.16 (0.88--1.53)                                            
  Log-additive   --           --               --                  1.25 (1.01--1.53)   0.036       1334.7   1599.0

**Abbreviations:** AIC, Akaike information criterion; BIC, Bayesian information criterion; NSCLC, nonsmall cell lung cancer.

###### 

Comparison of genotypic and allelic distribution of the four SNPs between pathologic stages I+II and III+IV (after adjusting for gender and age)

  SNP          Genotype, n (%)   *P*-value    Allele, n (%)   *P*-value   OR (95% CI)                        
  ------------ ----------------- ------------ --------------- ----------- ------------- ------------ ------- -------------------
  rs11134527   A/A               A/G          G/G                         A             G                    
   I+II        63 (42.9)         60 (40.8)    24 (16.3)       0.693       186 (63.3)    108 (36.7)   0.462   0.90 (0.67--1.20)
   III+IV      118 (63.3)        135 (44.3)   52 (17.0)                   371 (60.8)    239 (39.2)           
  rs74693964   C/C               C/T          T/T                         C             T                    
   I+II        138 (93.9)        9 (6.9)      0 (0.0)         0.760       285 (96.9)    9 (3.1)      0.749   0.88 (0.40--1.94)
   III+IV      284 (93.1)        21 (6.9)     0 (0.0)                     589 (96.6)    21 (6.9)             
  rs6062251    C/C               C/T          T/T                         C             T                    
   I+II        17 (11.6)         74 (50.3)    56 (38.1)       0.334       108 (36.7)    186 (63.3)   0.156   0.81 (0.60--1.08)
   III+IV      26 (8.5)          143 (46.9)   136 (44.6)                  195 (32.0)    415 (68.0)           
  rs4705343    T/T               T/C          C/C                         T             C                    
   I+II        63 (42.9)         63 (42.9)    21 (14.3)       0.422       189 (64.3)    105 (35.7)   0.248   1.19 (0.89--1.59)
   III+IV      141 (46.2)        133 (43.6)   31 (10.2)                   415 (68.0)    195 (32.0)           

**Abbreviation:** SNP, single nucleotide polymorphism.

###### 

Comparison of genotypic and allelic distribution of the four SNPs between AC and SCC (after adjusting for gender and age)

  SNP          Genotype, n (%)   *P*-value    Allele, n (%)   *P*-value   OR (95% CI)                        
  ------------ ----------------- ------------ --------------- ----------- ------------- ------------ ------- -------------------
  rs11134527   A/A               A/G          G/G                         A             G                    
   AC          96 (35.4)         124 (45.8)   51 (18.8)       0.015       316 (58.3)    226 (41.7)   0.005   0.65 (0.48--0.88)
   SCC         82 (48.5)         67 (39.6)    20 (11.8)                   231 (68.3)    107 (31.7)           
  rs74693964   C/C               C/T          T/T                         C             T                    
   AC          253 (93.4)        18 (6.6)     0 (0.0)         0.853       524 (96.7)    18 (3.3)     0.870   1.07 (0.49--2.32)
   SCC         157 (92.9)        12 (7.1)     0 (0.0)                     326 (96.4)    12 (3.6)             
  rs6062251    C/C               C/T          T/T                         C             T                    
   AC          25 (9.2)          121 (44.6)   125 (46.1)      0.344       171 (31.5)    371 (68.5)   0.364   0.87 (0.64--1.18)
   SCC         17 (10.1)         86 (50.9)    66 (39.1)                   120 (35.5)    218 (64.5)           
  rs4705343    T/T               T/C          C/C                         T             C                    
   AC          124 (45.8)        116 (42.8)   31 (11.4)       0.984       364 (67.2)    178 (32.8)   0.961   0.99 (0.73--1.34)
   SCC         76 (45.0)         73 (43.2)    20 (11.8)                   225 (66.6)    113 (33.4)           

**Abbreviations:** AC, adenocarcinoma; SCC, squamous cell carcinoma; SNP, single nucleotide polymorphism.

###### 

Comparison of the SNP distribution between European and Asian populations

  SNP in current study   Allelic frequencies in European population   Allelic frequencies in Eastern Asian population   *P* value
  ---------------------- -------------------------------------------- ------------------------------------------------- -----------
  rs11134527             G: 76%; A: 24%                               G: 43%; A: 57%                                    \<0.001
  rs74693964             C: 100%                                      C: 96%; T: 4%                                     0.043
  rs6062251              T: 38%; C: 62%                               T: 67%; C: 33%                                    \<0.001
  rs4705343              T: 83%; C: 17%                               T: 68%; C: 32%                                    0.014

**Abbreviation:** SNP, single nucleotide polymorphism.
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